Skip to content
DRM3TruthFoundry
Facts Fact Checker
What’s Newnew to the world vs developing The Readeryour subjects, your feeds, your alerts Discoverwhat to search right now Digeststhe day's briefs by topic and region Archivethe signed daily edition, every day Federal Spendingwhat the state bought, from the award record
Signalsthe day's biggest market moves Intellive public data feeds, charted and briefed Entitieswho the coverage keeps repeating
Smart Querycomposable queries over the index Monitorsstanding subjects on your cadence APIthe live read API and playground AgentsTruthFoundry for agents: MCP, pay-per-call, OpenAPI Pricingplans and the API entry tier
◆Read Today’s TruthFoundry News→-credits
Home News Facts Fact Checker
Read
What’s New The Reader Discover Digests Archive Federal Spending
Data
Signals Intel Entities
Tools
Smart Query Monitors API Agents Pricing

Celiac Disease Foundation

1 articles in the TruthFoundry index. Each links out to the original.

  • Teva reports positive Phase 2a results for celiac drug TEV-408 in gluten challenge trial · Teva's investigational IL-15 blocker TEV-408 reduced gluten-induced intestinal damage in a Phase 2a trial of 50 celiac patients.
DRM3TruthFoundry · Verified News Intelligence
A signed, dated record of world events, frozen day by day.

Read

News What's New Facts Fact Checker Discover The Reader Digests Archive Federal Spending

Data

Signals Intel Entities Smart Query Monitors

Build

Agents API Playground Pricing Trust

Company

About & sponsors Redactions & opt-out Status DRM3 Labs Terms Privacy Publishers Cookie settings
v1.59.15 © 2026 DRM3 Labs Corp.
DRM3 Labs Corp., 333 3rd Ave N, Suite 400, St. Petersburg, FL 33701

Analytics cookies? We would like to use Google Analytics to see which pages are useful. It sets cookies and shares usage data with Google. Nothing loads unless you accept, and you can change your mind any time under Cookie settings in the footer. Privacy policy